Pexastimogene devacirepvec

Pexastimogene devacirepvec is a gene pharmaceutical. It is currently being investigated in clinical studies.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

21 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

No data

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Renal cell carcinoma	D002292	EFO_0000376	—	1	1	—	—	—	1
Carcinoma	D002277	—	C80.0	1	1	—	—	—	1
Vaccinia	D014615	—	—	1	1	—	—	—	1

Indications Phases 1

No data

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Pexastimogene devacirepvec
INN	pexastimogene devacirepvec
Description	JX-594 is an oncolytic virus is designed to target and destroy cancer cells. It is also known as Pexa-Vec, INN pexastimogene devacirepvec) and was constructed in Dr. Edmund Lattime's lab at Thomas Jefferson University, tested in clinical trials on melanoma patients, and licensed and further developed by SillaJen.
Classification	Gene
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—